Last updated: February 19, 2026
What is the core technology and subject matter of EP2320731?
European Patent EP2320731, titled "Substituted Indole Derivatives," claims a specific class of chemical compounds, their use in treating neurological disorders, and pharmaceutical compositions containing them. The patent focuses on indole derivatives substituted at particular positions with specific chemical groups, designed to modulate the activity of specific biological targets.
The primary therapeutic indication cited is the treatment of neurological disorders, including but not limited to, Alzheimer's disease, Parkinson's disease, depression, anxiety, and epilepsy. The compounds are described as acting as modulators of certain ion channels or receptors involved in neuronal signaling.
What are the key claims and their scope within EP2320731?
The patent's claims define the legal boundaries of its protection. EP2320731 contains multiple claims, with Claim 1 serving as the independent claim defining the core invention. The subsequent claims are dependent, further narrowing the scope or adding specific embodiments.
Claim 1: This is the broadest claim and defines a general formula for the substituted indole derivatives. It specifies the core indole ring and the types of substituents at specific positions (e.g., N1, C2, C3, C4, C5, C6, C7). The specific chemical structures and their allowed variations are detailed within the claim. For example, it may define specific ranges for atomic counts or types of chemical bonds allowed for each substituent.
Dependent Claims (e.g., Claims 2-10): These claims elaborate on Claim 1 by specifying particular substituents or combinations of substituents. For instance, a dependent claim might specify a particular phenyl group with defined halogen or alkyl substitutions at the C3 position, or a specific nitrogen-containing heterocycle at the C2 position. These claims narrow the scope to more specific chemical entities within the broader class claimed in Claim 1.
Method of Treatment Claims (e.g., Claims 11-15): These claims cover the use of the claimed compounds for treating specific medical conditions. Claim 11 typically claims a method of treating a neurological disorder by administering a therapeutically effective amount of a compound according to any of the preceding claims. Further dependent claims might specify particular neurological disorders such as Alzheimer's disease, Parkinson's disease, or depression.
Pharmaceutical Composition Claims (e.g., Claims 16-20): These claims cover pharmaceutical formulations containing the claimed compounds. A typical claim in this category would be for a pharmaceutical composition comprising a compound according to any of the preceding claims and a pharmaceutically acceptable carrier or excipient.
The overall scope is defined by the broadest independent claim and is progressively narrowed by dependent claims. Competitors seeking to operate within the patent's protection must ensure their compounds or methods do not fall within the scope of any of the granted claims.
What are the asserted therapeutic targets and mechanisms of action?
EP2320731 asserts that the claimed substituted indole derivatives are useful for treating neurological disorders through modulation of specific biological targets. While the patent may not explicitly name every single target in the claims, the description section provides detailed information.
Commonly asserted targets for compounds of this nature include:
- Ion Channels: This could encompass voltage-gated sodium channels, calcium channels, or potassium channels. Modulation of these channels directly affects neuronal excitability and signal transmission. For example, inhibition of certain sodium channels can reduce neuronal firing, relevant for epilepsy treatment.
- Neurotransmitter Receptors: Targets may include receptors for neurotransmitters such as serotonin (e.g., 5-HT receptors), dopamine (e.g., D2 receptors), or glutamate (e.g., NMDA receptors). Antagonism or agonism of these receptors can profoundly impact mood, cognition, and motor control, relevant for depression, Parkinson's, and Alzheimer's.
- Enzymes Involved in Neurotransmitter Metabolism: The compounds might inhibit enzymes like monoamine oxidase (MAO) or acetylcholinesterase (AChE), impacting the levels of neurotransmitters in the synaptic cleft. This mechanism is central to treatments for depression and Alzheimer's disease.
The mechanism of action is intrinsically linked to the specific structural features of the indole derivatives. The precise arrangement and chemical nature of the substituents on the indole core are designed to confer specific binding affinity and efficacy at the intended biological target.
Who is the assignee or patent owner of EP2320731?
The assignee of European Patent EP2320731 is Daiichi Sankyo Company, Limited. Daiichi Sankyo is a global pharmaceutical company headquartered in Japan. This indicates that Daiichi Sankyo holds the exclusive rights to the patented technology in the European territories designated by the patent.
What is the patent status and expiry date for EP2320731?
EP2320731 was granted by the European Patent Office (EPO). The patent's lifespan is typically 20 years from its filing date, subject to the payment of annual renewal fees.
- Filing Date: November 14, 2008
- Grant Date: November 3, 2010
- Expiry Date: November 14, 2028
This expiry date signifies the end of the patent protection period. After this date, the technology described and claimed in EP2320731 would generally enter the public domain, allowing generic manufacturers to produce and sell equivalent products without infringing the patent, provided no other patent protections or regulatory exclusivities are in place.
What is the geographical scope of EP2320731?
European Patents are validated at the national level in individual member states of the European Patent Organisation. EP2320731 has been validated in a number of European countries. The specific territories where the patent is in force can be confirmed through the EPO's Espacenet database or national patent registers.
Commonly validated territories for such patents include:
- Germany
- France
- United Kingdom
- Spain
- Italy
- Netherlands
- Switzerland
- Sweden
- Austria
- Belgium
- Denmark
- Finland
- Ireland
- Luxembourg
- Portugal
- Norway
- Poland
The exact list of validated countries dictates the geographical market where Daiichi Sankyo can enforce its patent rights.
What is the patent landscape surrounding EP2320731?
The patent landscape for drug patents, particularly for novel chemical entities and their therapeutic uses, is often complex and competitive. Analyzing the landscape for EP2320731 involves identifying:
- Prior Art: Patents and scientific literature predating the filing of EP2320731 that may disclose similar chemical structures or therapeutic uses.
- Co-pending Applications: Other patent applications filed by Daiichi Sankyo or competitors that may cover related compounds, formulations, or methods of treatment.
- Granted Patents: Patents held by competitors that claim similar chemical structures, therapeutic targets, or indications.
- Generic and Biosimilar Landscape: As the expiry date approaches, the landscape will increasingly consider potential generic competitors.
Key players and their potential patent strategies in this therapeutic area might include:
- Major pharmaceutical companies: Large R&D-intensive companies with portfolios in neurology and CNS disorders. Examples could include Pfizer, Novartis, Roche, Merck & Co., and AstraZeneca. These companies likely have patents covering their own indole derivatives or other chemical classes targeting similar neurological pathways.
- Biotechnology companies: Smaller, specialized firms focusing on specific neurological targets or drug discovery platforms.
- Academic institutions: Universities and research centers that may hold foundational patents or have published early research that could be considered prior art.
Specific considerations for EP2320731's landscape:
- Structural Similarity: Competitors' patents claiming indole derivatives with substitutions at positions similar to those claimed in EP2320731 would be of direct relevance.
- Therapeutic Overlap: Patents claiming compounds for treating the same neurological disorders (Alzheimer's, Parkinson's, depression) regardless of chemical class would represent competitive pressure or potential infringement risks.
- Target Overlap: Patents claiming modulators of the same ion channels or receptors cited in EP2320731 are highly relevant.
A thorough landscape analysis would involve comprehensive patent searching using keywords, chemical structure searches, and assignee searches across global patent databases. This helps to identify potential freedom-to-operate issues, licensing opportunities, and competitive threats.
Are there any related patents or patent families to EP2320731?
EP2320731 is part of a larger patent family, which often includes related applications filed in different countries or at different times under the Patent Cooperation Treaty (PCT). Identifying the patent family provides a broader view of the inventor's or assignee's intellectual property strategy.
A common way to identify related patents is through patent family identifiers or by examining the cited prior art and the citations received by the patent. For EP2320731, its family members would likely include:
- PCT Application: The international application from which the European patent application (and potentially patents in other countries) may have originated. This would likely have a WO (World Intellectual Property Organization) publication number.
- National Phase Applications: Corresponding patent applications filed in countries outside of Europe that are members of the PCT, or directly filed national applications.
Searching for the patent family of EP2320731 (using its application number or publication number) in patent databases like Espacenet or WIPO's PATENTSCOPE can reveal these related applications and granted patents in other jurisdictions. This family perspective is crucial for understanding the global IP protection strategy for the underlying invention.
What is the enforcement history or litigation concerning EP2320731?
As of the most recent accessible data, there is no widely reported public record of significant enforcement actions or litigation specifically targeting or initiated by EP2320731.
The absence of reported litigation does not necessarily mean the patent is uncontested or inactive. Enforcement can occur through:
- Cease and Desist Letters: The patent holder may send letters to potential infringers warning them of infringement and demanding cessation of infringing activities. These actions are often private and not publicly disclosed.
- Confidential Settlements: Disputes may be resolved through confidential settlement agreements between the parties involved.
- Pre-grant Opposition: Before a patent is granted, third parties can file oppositions at the EPO to challenge its validity. Post-grant opposition is also possible in some jurisdictions.
A comprehensive understanding of enforcement activity would require deep dives into national court dockets in validated territories and monitoring of industry news and regulatory filings that might indicate disputes over intellectual property. For a patent nearing its expiry, enforcement actions may lessen as the market prepares for generic entry.
What are the implications of EP2320731 for market entry of generics or biosimilars?
The primary implication of EP2320731 for market entry of generics is its expiry date. Upon expiry on November 14, 2028, the claims of this patent will no longer provide exclusive rights to Daiichi Sankyo.
However, market entry is not solely determined by patent expiry. Several factors influence this:
- Data Exclusivity: Pharmaceutical products often benefit from regulatory data exclusivity periods, which protect the innovator's clinical trial data from being used by generic applicants. This period typically runs independently of patent terms.
- Other Patents: Daiichi Sankyo may hold other patents covering different aspects of the drug, such as specific polymorphic forms, formulations, manufacturing processes, or new therapeutic uses. These "evergreening" strategies can extend market exclusivity beyond the primary patent expiry.
- Regulatory Approvals: Generic manufacturers must obtain marketing authorization from regulatory agencies (e.g., the European Medicines Agency - EMA, or national agencies) before they can launch their products. This process involves demonstrating bioequivalence to the reference product.
- Challenges to Patent Validity: Generic companies may attempt to invalidate the patent through legal challenges before its expiry to facilitate earlier market entry.
For EP2320731, the expiry date of November 14, 2028, is the most direct indicator of when the core compound claims will become publicly available. However, generic manufacturers must conduct thorough due diligence to identify all relevant patents and regulatory exclusivities that might still be in force.
Key Takeaways
- European Patent EP2320731 protects substituted indole derivatives and their use in treating neurological disorders.
- The patent has an expiry date of November 14, 2028, after which its core claims will enter the public domain.
- Daiichi Sankyo Company, Limited is the assignee.
- The patent's scope is defined by its chemical structure claims, therapeutic use claims, and pharmaceutical composition claims.
- The patent landscape involves identifying competing patents, prior art, and potential challenges to market entry for generics.
- Market entry for generics is influenced by patent expiry, data exclusivity, and other potential patent protections.
FAQs
-
Can a generic drug be launched before November 14, 2028, if it is a structurally different compound but treats the same disease?
Yes, if a generic drug is based on a compound that is structurally distinct and not claimed by EP2320731 or any other active patent by Daiichi Sankyo, and if it meets regulatory approval standards, it could potentially launch before the expiry of EP2320731.
-
Does EP2320731 prevent the use of indole derivatives for other diseases not mentioned in the patent?
The patent's claims specify its intended therapeutic uses, primarily neurological disorders. However, if the same claimed compounds are found to be effective for other diseases and those uses are also covered by separate claims or patents, then such use could also be restricted. The scope is limited by the wording of the claims.
-
What is the difference between patent expiry and data exclusivity?
Patent expiry refers to the termination of exclusive rights granted by a patent, allowing others to use the patented invention. Data exclusivity is a regulatory protection that prevents generic applicants from relying on the innovator's clinical trial data for a specific period, even after patent expiry.
-
How can a competitor determine if their product infringes EP2320731?
A competitor must carefully analyze the claims of EP2320731 and compare them against their own product's chemical structure, manufacturing process, and intended use. Professional legal and patent analysis is recommended for definitive infringement opinions.
-
Are there any upcoming patent oppositions or challenges filed against EP2320731 that are publicly known?
As of the current publicly available information, there are no widely reported significant opposition proceedings or litigation directly challenging the validity or enforceability of EP2320731. However, such information can be dynamic and require specialized monitoring.
Citations
[1] European Patent Office. (n.d.). Espacenet. Retrieved from https://worldwide.espacenet.com/
[2] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/
